Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박현준 | - |
dc.contributor.author | 문경현 | - |
dc.contributor.author | 이승욱 | - |
dc.contributor.author | 이원기 | - |
dc.contributor.author | 감성철 | - |
dc.contributor.author | 이준호 | - |
dc.contributor.author | 박남철 | - |
dc.date.accessioned | 2022-07-16T05:17:35Z | - |
dc.date.available | 2022-07-16T05:17:35Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2014-04 | - |
dc.identifier.issn | 2287-4208 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/160233 | - |
dc.description.abstract | Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for erectile dysfunction (ED). Since the launch of sildenafil, several drugs−including mirodenafil, sildenafil citrate (sildenafil), tadalafil, vardenafil HCL (vardenafil), udenafil, and avanafil−have become available. Mirodenafil is a newly developed pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor. Mirodenafil was launched in Korea in 2007, and an orally disintegrating film of mirodenafil was developed in 2011 for benefitting patients having difficulty in swallowing tablets. This study aimed to review the pharmacokinetic characteristic profile of mirodenafil and report evidence on its efficacy in the case of ED. In addition, we reviewed randomized controlled studies of mirodenafil’s daily administration and efficacy for lower urinary tract symptoms. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한남성과학회 | - |
dc.title | Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature | - |
dc.title.alternative | Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 이승욱 | - |
dc.identifier.doi | 10.5534/wjmh.2014.32.1.18 | - |
dc.identifier.bibliographicCitation | The World Journal of Men's Health, v.32, no.1, pp.18 - 27 | - |
dc.relation.isPartOf | The World Journal of Men's Health | - |
dc.citation.title | The World Journal of Men's Health | - |
dc.citation.volume | 32 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 18 | - |
dc.citation.endPage | 27 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001868610 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Erectile dysfunction | - |
dc.subject.keywordAuthor | Phosphodiesterase 5 inhibitors | - |
dc.subject.keywordAuthor | Review | - |
dc.subject.keywordAuthor | Treatment efficacy | - |
dc.identifier.url | https://wjmh.org/DOIx.php?id=10.5534/wjmh.2014.32.1.18 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.